$ACT Company News What a week: Botox haze, merger

New Post Public Reply Private Reply Replies (0) Message Board

Dec 6, 2014 at 9:38 AM

$ACT Company News

What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Actavis, Allergan close to a deal 8:33 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Allergan, Actavis near cash-and-stock deal: WSJ 1:48 p.m. Nov. 16, 2014 - Andria Cheng
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
Ackman urges Allergan to open sale process, negotiate 10:33 a.m. Nov. 7, 2014 - Chelsey Dulaney
Actavis sales surge, exceed forecasts 7:51 a.m. Nov. 5, 2014 - MarketWatch.com
Media, consumer-based company earnings to test stock rally 4:30 a.m. Nov. 2, 2014 - Wallace Witkowski
Pfizer sales fall less than expected 7:34 a.m. Oct. 28, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan

Ad Comm likes CAZ-AVI for complicated infections but not for Gram-negatives 3:44 p.m. Dec. 5, 2014 - Seeking Alpha
Activist Investors Torn on Private Equity Partnerships 12:48 p.m. Dec. 5, 2014 - TheStreet.com
Goldman's Parker Calls Allergan Pursuit a 'One-time Opportunity' 9:17 a.m. Dec. 5, 2014 - TheStreet.com
Great Stocks In 2014: Airline, Video Game, Drugs Lead 5:53 p.m. Dec. 4, 2014 - Investors Business Daily
Great Stocks: Mallinckrodt Buys Raise Profit Margins 5:20 p.m. Dec. 4, 2014 - Investors Business Daily
Dodge & Cox's Top New Buys of Q3 11:26 a.m. Dec. 4, 2014 - GuruFocus.com
Oncolytics Files for Orphan Drug Designation for Reolysin - Analyst Blog 4:30 p.m. Dec. 3, 2014 - Zacks.com
Pain Therapeutics' Remoxy Would Be A Good Fit For Any Of These Experienced Companies 3:41 p.m. Dec. 3, 2014 - Seeking Alpha
Ad Comm review approaches for Actavis anti-infective combo 1:46 p.m. Dec. 3, 2014 - Seeking Alpha
Zoetis in a Growing Global Animal Health Industry 10:32 a.m. Dec. 3, 2014 - GuruFocus.com
Cramer's Mad Money - Deckers Is About More Than Just Uggs (12/2/14) 5:33 a.m. Dec. 3, 2014 - Seeking Alpha
Actavis Launches Generic of Shire's ADHD Drug Intuniv - Analyst Blog 6:45 p.m. Dec. 2, 2014 - Zacks.com
U.S. Stock Mutual Funds Led Advance In November 5:19 p.m. Dec. 2, 2014 - Investors Business Daily
Top Funds Gobble Up Tech And Medical Stocks 5:19 p.m. Dec. 2, 2014 - Investors Business Daily
Jim Cramer's 4 Best Stock Picks for the Health Care Sector 11:23 a.m. Dec. 2, 2014 - TheStreet.com
3 Best Performing Stocks in November - Analyst Blog 10:28 a.m. Dec. 2, 2014 - Zacks.com
Larry Robbins Lives Up to Reputation for Investing in Healthcare Sector 3:59 p.m. Dec. 1, 2014 - GuruFocus.com
Celgene Hits 52-Week High on Positive CHMP Opinion - Analyst Blog 3:14 p.m. Dec. 1, 2014 - Zacks.com
UPDATE: Actavis Launches Generic Version of Intuniv 3:06 p.m. Dec. 1, 2014 - benzinga.com
Mylan (MYL) Sued By Baxter for Generic Filing of Brevibloc - Analyst Blog 4:30 p.m. Nov. 28, 2014 - Zacks.com

Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 4:46 p.m. Dec. 5, 2014 - PR Newswire - PRF
No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan, an Industrial Info News Alert 6:15 a.m. Dec. 3, 2014 - Marketwired
Stock Updates on Pharma Services - Avanir Pharma, Zoetis, Allergan, Mallinckrodt, and Actavis 8:30 a.m. Nov. 25, 2014 - PR Newswire - PRF
Critical Alerts For Gold Fields, Actavis, Trina Solar Limited, Alcoa and Herbalife Released By InvestorsObserver 9:31 a.m. Nov. 19, 2014 - PR Newswire - PRF
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 10:32 a.m. Nov. 17, 2014 - PR Newswire - PRF
Valeant Comments On Allergan Announcement 9:29 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue 9:15 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer 8:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients 8:00 a.m. Nov. 13, 2014 - PR Newswire - PRF
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 6:45 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 6:30 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4:15 p.m. Oct. 31, 2014 - PR Newswire - PRF
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
Actavis Confirms Generic Quillivant XR® Patent Challenge 8:00 a.m. Oct. 16, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Ambulatory Surgery Center in Alabama Breaks Ground

Breaking New Ground: USOP and SOS Lead the Charge You can almost hear the construction noise starting up in Montgomery, Alabama, where U.S. Orthopaedic Partners (USOP) and Southern Orthopaedic Surgeons (SOS) have just launched an ambitious new project. They're not just cutting ceremonial ribbons; they're slicing into the future of orthopedic care in Central Alabama. The...

DICK'S Sporting Goods Faces Investor Lawsuit Deadline Looms

A Rough Tumble for DICK'S Sporting Goods Let's cut to the chase: DICK'S Sporting Goods, Inc. (NYSE:DKS) just took a nosedive. We're talking a hard 30.68% fall on the stock, plummeting to $124.31 a share as of August 25, 2026. Now, if you were caught up in this whirlwind as an investor, you'd be forgiven for having a few choice words for the powers that be over at DICK'S....

EQT's Strategic Moves in Q3 2026 Amid Strong Execution

Inside EQT's Third Quarter Performance EQT Corporation has rolled out its third quarter 2026 results, and boy, they’ve been playing their cards with some finesse. The company's sporting a strong showing despite the tricky currents in the natural gas market where prices took a nosedive. What's keeping EQT upright, you ask? It's their smart marketing maneuvers and a...

Ramaco's Strategic Push into Critical Minerals Discussed

An Industry Insider Speaks on Global Stage In the shuffle of corporate presentations and industry meet-ups, let's put Ramaco Resources and their executive vice president, Mike Woloschuk, into sharper focus. In Paris, he's set to address the plenary session of the International Energy Agency's Coal Industry Advisory Board. His talk titled 'Bringing Critical Minerals...

CookieYes Gains Shopify Badge, Ramps Up Installs

Shopify Community Welcomes CookieYes with Open Arms In a world where compliance increasingly dictates playbooks, CookieYes scoring the ‘Built for Shopify’ badge sends a message across boardrooms worldwide—straight from middle-of-nowhere Milton Keynes! Awarded on October 9, 2026, this gives you a hint of what it means when performance and seamless integration are...

Navigating Market Uncertainty with Financial Planning

Staying Calm Amid Market Chaos The market's like a roller coaster more often than not, and when headlines scream panic, even the most seasoned of us can begin to doubt our strategies. Jennifer Prosise from The Voyager Group, Ltd., in Joliet, IL, calls out this high-stakes game in HelloNation, emphasizing how financial planning serves as our anchor in the stormy seas of...

Replay Sports Cards Nets STAR Award for Innovation

A New Era for Franchise Onboarding Just when you think the sports card world couldn't get any more niche, along comes Replay Sports Cards thumping its chest with some serious innovation. This Charlotte-based franchise just snagged the Franchise Innovation Award from Franchise Update Media. Yep, they're the only ones getting tips of the hat for the Most Innovative...

DexCom Faces Scrutiny: Fiduciary Breach Questioned

Is DexCom’s Leadership Under The Gun? Here's the scoop, folks—DexCom, Inc. (NASDAQ:DXCM) has been hit with some serious questions recently. Nothing like a potential fiduciary breach to shake things up. October 27, 2026, is when the news broke, with Halper Sadeh LLC taking the reins on this investigation. They’re poking around to see if DexCom’s top dogs stumbled...

WORKPRO® Tools Extends Partnership With NBCF Through 2026

A Partnership that Proves its Mettle Here's an alliance that's not just about screws and hammers, folks. WORKPRO® Tools is hitting the nail on the head once more by extending its partnership with the National Breast Cancer Foundation (NBCF) into year seven. You don't often see corporations sticking with the same charitable commitment for this long, but here we are. This...

Flex LNG Readies for Crucial Q3 Earnings Reveal

Anticipation Builds for Flex LNG's Upcoming Q3 Reveal The air's thick with expectation as Flex LNG gears up to lay its cards on the table for the third quarter of 2026. Come November 11, the company will spill the beans on its financial dance over the last few months, promising to unfurl the numbers early in the morning like a farmer checking crops at dawn—07:00 CET...